Learning Points. Raymond Blum, M.D. Antimicrobial resistance among gram-negative pathogens is increasing
|
|
- Gillian Cassandra Stevens
- 6 years ago
- Views:
Transcription
1 Raymond Blum, M.D. Learning Points Antimicrobial resistance among gram-negative pathogens is increasing Infection with antimicrobial-resistant pathogens is associated with increased mortality, length of stay, and costs Few new antimicrobials have been recently approved Practice appropriate initial empiric therapy and de-escalation once culture and susceptibility data become available
2 Prior to 1980 gram-negatives predominated among nosocomial infections Since 2003 a significant increase Reemergence not a specific organism 60% of nursing home bacteremias are gramnegative In 2003, gram-negative bacilli in the ICU were associated with 1 : 71.1% of urinary tract infections 65.2% of pneumonia episodes 33.2% of surgical site infections 23.8% of bloodstream infections
3 Arch Int Med 166:1289. Femoral Other Organism Gram Positive 16 (44%) 47 (90%) Gram Negative 14 (39%) 4 (7%) Yeast 6 (16%) 1 (2%)
4 ICU Infections Associated With Gram-negative Bacilli in 2003 (%) NNIS epidemiologic data of ICU infections in Pneumonia episodes (n = 4365) 23.8 Bloodstream infections (n = 2351) 71.1 Urinary tract infections (n = 4109) 33.8 Surgical site infections (n = 2984) NNIS = National Nosocomial Infections Surveillance System; ICU = Intensive Care Unit Gaynes R, et al. Clin Infect Dis. 2005;41: Type of Infection Pneumonia (n=4365) Bloodstream infection (n=2351) Urinary tract infection (n=4109) Surgical site infection (n=2984) E coli, Enterobacter Acinetobacter spp, % spp, % P aeruginosa, % K pneumoniae, % % Boxes indicate most prevalent gram-negative species isolated for type of infection Data from the National Nosocomial Infections Surveillance (NNIS) System, Percentages of bacterial ICU isolates are shown. Gaynes R, Edwards JR. Clin Infect Dis. 2005;41: Differs from gram positive LPS activates immune system Ability to bind to receptors Production of exotoxins pseudomonas e.g.
5 Diplococci Neisseria Meningitidis Neisseria Gonorrhea Capnocytophaga dog bites, asplenia Paturella cat bites Non-lactose Fermenters Pseudomonas Proteus Serratia Acinetobacter Citrobacter (some) Enterobacter (some) Enteric pathogens Salmonella Shigella Camplobacter Vibrio E.Coli
6 Gram Negative Bugs Lactose Fermenting Rods E. coli 90% of UTIs Klebsiella Citrobacter (some) Enterobacter (some) HACEK Haemophilus Actinobacillus Cardiobacterium Eikenella Kingella Cause of endocarditis, bone and joint infections Resistance is increasing among many gramnegative pathogens 1 Infection with resistant pathogens is associated with negative health outcomes 3,4 Mortality/morbidity Length of ICU and hospital stay Healthcare costs No new antibiotic classes under development 2 Highlights the need to optimize existing classes of antimicrobials 1. Gaynes R, et al. Clin Infect Dis. 2005;41: Spellberg B, et al. Clin Infect Dis. 2004;38: Lautenbach E, et al. Infect Control Hosp Epidemiol. 2006;27: Cosgrove, S et al. Clin Infect Dis. 2006;42:S82-S89..
7 Over 100 have been described Chromosomal and plasmid Confer resistance to all cephalosporins, monobactams and penicillins Often resistant to aminoclycosides, quinolones Carbapenems drugs of choice Some sensitive to tigecycline 30% Enterobacter resistant to 3 rd generation cephalosporin in % Klebsiella 60% of surveyed ICUs had ESBLs Hidden resistance ESBLs are difficult to detect Adverse outcomes associated with failure to detect ESBLs Only 70% of labs screen for ESBLs Also known as MDR (multi-drug resistant) PDR (pan-drug resistant) Klebsiella, Acinetobacter and Pseudomonas Resistant to all cephalosporins, penicillins, carbapenems Aminoglycosides amikacin Colisitin
8 Bloodstream Isolates Within 48 hours
9 Pathogen Prevalence n (%) Mortality a n (%) P aeruginosa 57 (14.3) 16 (28.6) K pneumoniae 13 (3.3) 3 (23.1) Enterobacter spp 13 (3.3) 1 (7.7) VAP is often associated with gram-negative pathogens and high mortality 1-3 E coli 12 (3.0) 3 (25.0) Acinetobacter spp 8 (2.0) 4 (50.0) Adapted fromkollef MH, et al. Chest. 2006;129: Kollef MH, et al. Chest. 2006;129: Luna CM, et al. Eur Respir J. 2006;27: Chastre J, Fagon J-Y. Am J Respir Crit Care Med. 2002;165: Resistance is a complex problem 1,2 Multiple/concurrent mechanisms Expanding mechanisms >500 discrete β-lactamases Evolution of carbapenemases Efflux pumps Permeability changes Selective antimicrobial pressure favors amplification of resistant bacteria Adverse impact on patient outcomes 3 Mortality, length of stay, healthcare costs 1. Talbot GH, et al. Clin Infect Dis. 2006;42: Bush K. Clin Infect Dis. 2001;32: Cosgrove SE. Clin Infect Dis. 2006;42(S2):S82-S89.
10 Imipenem Ceftazidime 25 Proportion of resistant isolates (%) Independent study of 8,244 P aeruginosa ICU isolates collected from 1994 to 2000 reported the following average susceptibilities 2 : tobramycin, 87% imipenem, 83% amikacin, 90% piperacillin-tazobactam, 78% cefepime, 71% Year Data from the National Nosocomial Infections Surveillance System, ICU isolates. Adapted with permission from: Gaynes R, et al. Clin Infect Dis. 2005;41: Gaynes R, et al. Clin Infect Dis. 2005;41: Neuhauser M, et al. JAMA. 2003;289: Resistance to imipenem Resistance to ceftazidime No n = 114 Imipenem No. (%) of patients, by previous antibiotic received Yes n = 21 Third-generation Cephalosporin No n = 73 Yes n = 62 Fluoroquinolone No n = 100 Yes n = (16.7) 11 (52.4) a 12 (16.4) 18 (29.0) 18 (18.0) 12 (34.3) d 17 (14.9) 7 (33.3) 6 (8.2) 18 (29.0) b 14 (14.0) 10 (28.6) Resistance to 35 (30.7) 11 (52.4) 25 (34.2) 21 (33.9) 26 (26.0) 20 (57.1) ciprofloxacin c a P =.0009; b P =.003; c P =.001; d P =.05. All P values are for comparisons between the No and Yes groups. Data from a prospective single-icu study including 135 patients with VAP admitted between January 1994 and August (93%) of patients had received antibiotics within 15 days prior to receiving the diagnosis of VAP. Trouillet JL, et al. Clin Infect Dis. 2002;34: Imipenem Amikacin Ceftazidime 70 Proportion of resistant isolates (%) Year Data from the National Nosocomial Infections Surveillance System, ICU isolates. Adapted with permission from: Gaynes R, et al. Clin Infect Dis. 2005;41: Recent reports of rapid emergence of resistance to tigecycline among Acinetobacter spp worrisome 2-4 Efflux-based mechanism may play a role 4 1. Gaynes R, et al. Clin Infect Dis. 2005;41: Peleg AY, et al. J Antimicrob Chemother. 2007;59: Navon-Venezia S, et al. J Antimicrob Chemother. 2007;59: Peleg AY, et al. Antimicrob Agents Chemother In press.
11 Differs from gram positive LPS activates immune system Ability to bind to receptors Production of exotoxins pseudomonas e.g. E coli K pneumoniae 25 Proportion of resistant isolates a Year Data from the National Nosocomial Infections Surveillance System, ICU isolates. a Includes intermediately susceptible or resistant isolates. Adapted with permission from: Gaynes R, et al. Clin Infect Dis. 2005;41: Gaynes R, Edwards JR. Clin Infect Dis. 2005;41: Association of MDR P aeruginosa With Mortality, LOS, and Cost 1,2 2 2 Mortality LOS (21%) (12%) (20 d) (10 d) P =.04 P = Cost ($22,116) ($54,081) Multiresistant Nonresistant Percent, Dollars (000), Days MDR = multidrug-resistant; LOS = length of stay 1. Harris A, et al. Clin Infect Dis. 1999;28: Aloush V, et al. Antimicrob Agents Chemother. 2006;50:43-48.
12 Negative Outcomes Associated With Resistant Gram-Negative Infections Infection with imipenem-resistant P aeruginosa associated with higher mortality, LOS, and hospital costs Outcome Imipenemsusceptible Imipenem -resistant P value Mortality 16.7% 31.1% <.001 a LOS (days) Hospital costs $ $ <.001 a Relative risk, 1.86; 95% CI, ; LOS = length of stay Adapted from: Lautenbach E, et al. Infect Cont Hosp Epid. 2006;27: Number of New Antimicrobial Agents Approved Period Spellberg B, et al. Clin Infect Dis. 2004;38: Of 89 drugs approved in 2002, none was an antimicrobial 1 1. Infectious Diseases Society of America. Bad Bugs, No Drugs: As Antibiotic Discovery Stagnates, A Public Health Crisis Brews. July, Accessed March 17, Spellberg B, et al. Clin Infect Dis. 2004;38: The use of an antimicrobial agent that is correct on the basis of all available clinical, pharmacologic, and microbiologic evidence 1 Includes the following practices 1-4 : Initiate broad-spectrum empiric treatment Use optimal dosing regimens (dose, dosing interval, infusion time) De-escalate therapy to narrower spectrum agents when culture and susceptibility data and patient response assessments are available Utilize adequate treatment duration to reduce or eradicate bacterial burden while minimizing risk of superinfection Avoid duplicative combination regimens 1. Harbarth S, et al. Clin Infect Dis. 2007;44: Rodloff AC, et al. J Antimicrob Chemother. 2006;58: Dellit TH, et al. Clin Infect Dis. 2007;44: American Thoracic Society/Infectious Diseases Society of America. Am J Respir Crit Care Med. 2005;171:
13 Empiric therapy options when potentially drugresistant gram-negative pathogens are suspected in late onset HAP, VAP, and HCAP 1 Potential Pathogen Pseudomonas aeruginosa Klebsiella pneumoniae (ESBL-producing) Acinetobacter spp Antimicrobial Therapy Antipseudomonal cephalosporin Or Antipseudomonal carbapenem Or β-lactam/β-lactamase inhibitor Plus Antipseudomonal fluoroquinolone Or Aminoglycoside HAP = Hospital-acquired pneumonia; VAP = Ventilator-associated pneumonia; HCAP = Healthcare-associated pneumonia (as per American Thoracic Society Guidelines) Adapted with permission from: American Thoracic Society/Infectious Diseases Society of America. Am J Respir Crit Care Med. 2005;171: Selected recommendations from the guidelines: Collect cultures from all patients prior to initiating therapy; however, do NOT delay treatment of critically ill patients Early, appropriate, broad-spectrum, empiric antibiotic therapy and adequate doses Consider de-escalation once culture and susceptibility data are available Consider duration of therapy American Thoracic Society/Infectious Diseases Society of America. Am J Respir Crit Care Med. 2005;171: Initial broad-spectrum therapy followed by narrowing or discontinuation of antimicrobials after obtaining susceptibility results and observing the patient s clinical course 1 Balances the need to provide broad-spectrum treatment with the need to limit antimicrobial exposure, in order to minimize the emergence of resistance 2 Endorsed recently in the IDSA/SHEA antimicrobial stewardship guidelines 3 1. Park DR, et al. Respir Care. 2005;50: Kollef MH. Drugs. 2003;63: Dellit TH, et al. Clin Infect Dis. 2007;44:
14 Obtain culture specimens prior to initiating therapy Use updated, accurate institutional and unit-specific antibiograms Awareness of the pathogens and their susceptibilities most likely to be associated with infection Include in empiric regimen treatment for potentially resistant pathogens associated with infection type For example: P aeruginosa, Acinetobacter spp, Klebsiella pneumoniae, Enterobacter spp, and Staphylococcus aureus Modify therapy once culture and susceptibility results become available Switch to narrower-spectrum agents as appropriate Kollef MH. Drugs. 2003;63: Initial therapy should be broad to avoid inadequate treatment Determined by local data Use guidelines and know the risk factors for resistance Don t treat longer than necessary to eradicate the pathogen Based on clinical data and follow-up cultures, as available Serious hospital-acquired acquired infection suspected Obtain appropriate microbiological samples for culture and special stains Begin empiric antibacterial treatment with a combination of agents targeting the most common pathogens based on local data Follow clinical parameters: temperature, white blood cell count, chest radiograph, P a O 2 /F i O 2 hemodynamic parameters, organ function De-escalate antibacterials based on results of clinical microbiology data Continue to follow clinical parameters Search for superinfection, No Significant clinical abscess formation, improvement after hours noninfectious of antibacterial treatment? causes of fever/inflammation, Yes inadequate tissue Discontinue penetration of antibacterial after a 7- antibacterials to day course based on site of infection and clinical response Adapted from: Kollef MH. Drugs. 2003;63: Sepsis costs up to $50000 per patient $17 Billion annually in the US Mortality of 25-50% 2 nd leading cause of death in ICUs 10 th leading cause of death overall Survivors has significant disabilities
15 Organ and stem cell transplants Liver Failure Albumin <3mg/dl Diabetes Pulmonary Disease ESRD HIV Steroids Elderly Fever +/- Chills SIRS Confusion Respiratory Failure Septic Shock GI sxs Petichiae, purpura
16 Binding of ligands to Toll-like receptors LPS Flagellin Lipoproteins Know local resistance patterns Antibiograms are helpful Note differences between community, hospital and special units Inappropriate empiric treatment higher mortality Aid to appropriate empiric treatment Need to be interpreted They must be unit specific ICU, OPD, Bone Marrow etc Should include source Minimum of 30 unique isolates
17 Kang CI, et al Anti Agent Chemo 49:760
18 Kang CI, et al Anti Agent Chemo 49:760
19 Derivative of minocycline Activity against MRSA, VRE, ESBL acinetibacter Approved SSTI, GI infections Role in VAP not clear Polymixin E Activity against MDR- GNR including pseudomonas Nephrotoxicity and CNS toxicity
20 Treatment depends on severity Complicated Chronic catheter Epidemiology Prior treatment Local resistance patterns Quinolones no longer initial drug of choice Neutropenic patients Potential for resistance
21 One of the more challenging infections to diagnose and treat 30% mortality rate Peritonitis Spontaneous Secondary Tertiary Cholangitis Diverticulitis
22
23 Use only if necessary not for incontinence Use only as long as necessary Remove post-op Consider other options Intermittent, suprapubic, condom Keep system closed Unobstructed flow Need to consider host Immune compromised- neutropenic Catheters IV, urinary Prior antimicrobials Source of infection urine, biliary, pneumonia Severity of illness Hospital ecology Resistance patterns Learning Points Antimicrobial resistance among gram-negative pathogens is increasing Infection with antimicrobial-resistant pathogens is associated with increased mortality, length of stay, and costs Few new antimicrobials have been recently approved Practice appropriate initial empiric therapy and de-escalation once culture and susceptibility data become available
Appropriate antimicrobial therapy in HAP: What does this mean?
Appropriate antimicrobial therapy in HAP: What does this mean? Jaehee Lee, M.D. Kyungpook National University Hospital, Korea KNUH since 1907 Presentation outline Empiric antimicrobial choice: right spectrum,
More informationSepsis is the most common cause of death in
ADDRESSING ANTIMICROBIAL RESISTANCE IN THE INTENSIVE CARE UNIT * John P. Quinn, MD ABSTRACT Two of the more common strategies for optimizing antimicrobial therapy in the intensive care unit (ICU) are antibiotic
More informationAntimicrobial Cycling. Donald E Low University of Toronto
Antimicrobial Cycling Donald E Low University of Toronto Bad Bugs, No Drugs 1 The Antimicrobial Availability Task Force of the IDSA 1 identified as particularly problematic pathogens A. baumannii and
More informationManagement of Hospital-acquired Pneumonia
Management of Hospital-acquired Pneumonia Adel Alothman, MB, FRCPC, FACP Asst. Professor, COM, KSAU-HS Head, Infectious Diseases, Department of Medicine King Abdulaziz Medical City Riyadh Saudi Arabia
More informationThe International Collaborative Conference in Clinical Microbiology & Infectious Diseases
The International Collaborative Conference in Clinical Microbiology & Infectious Diseases PLUS: Antimicrobial stewardship in hospitals: Improving outcomes through better education and implementation of
More information4/3/2017 CLINICAL PEARLS: UPDATES IN THE MANAGEMENT OF NOSOCOMIAL PNEUMONIA DISCLOSURE LEARNING OBJECTIVES
CLINICAL PEARLS: UPDATES IN THE MANAGEMENT OF NOSOCOMIAL PNEUMONIA BILLIE BARTEL, PHARMD, BCCCP APRIL 7 TH, 2017 DISCLOSURE I have had no financial relationship over the past 12 months with any commercial
More informationMono- versus Bitherapy for Management of HAP/VAP in the ICU
Mono- versus Bitherapy for Management of HAP/VAP in the ICU Jean Chastre, www.reamedpitie.com Conflicts of interest: Consulting or Lecture fees: Nektar-Bayer, Pfizer, Brahms, Sanofi- Aventis, Janssen-Cilag,
More informationAntimicrobial stewardship in managing septic patients
Antimicrobial stewardship in managing septic patients November 11, 2017 Samuel L. Aitken, PharmD, BCPS (AQ-ID) Clinical Pharmacy Specialist, Infectious Diseases slaitken@mdanderson.org Conflict of interest
More informationInfectious Disease Issues in the Intensive Care Unit
Infectious Disease Issues in the Intensive Care Unit Catherine Liu, M.D. Assistant Clinical Professor Division of Infectious Diseases University of California, San Francisco Overview Emerging antibiotic
More informationNosocomial Infections: What Are the Unmet Needs
Nosocomial Infections: What Are the Unmet Needs Jean Chastre, MD Service de Réanimation Médicale Hôpital Pitié-Salpêtrière, AP-HP, Université Pierre et Marie Curie, Paris 6, France www.reamedpitie.com
More informationDr. Shaiful Azam Sazzad. MD Student (Thesis Part) Critical Care Medicine Dhaka Medical College
Dr. Shaiful Azam Sazzad MD Student (Thesis Part) Critical Care Medicine Dhaka Medical College INTRODUCTION ICU acquired infection account for substantial morbidity, mortality and expense. Infection and
More informationAntimicrobial stewardship: Quick, don t just do something! Stand there!
Antimicrobial stewardship: Quick, don t just do something! Stand there! Stanley I. Martin, MD, FACP, FIDSA Director, Division of Infectious Diseases Director, Antimicrobial Stewardship Program Geisinger
More informationSafe Patient Care Keeping our Residents Safe Use Standard Precautions for ALL Residents at ALL times
Safe Patient Care Keeping our Residents Safe 2016 Use Standard Precautions for ALL Residents at ALL times #safepatientcare Do bugs need drugs? Dr Deirdre O Brien Consultant Microbiologist Mercy University
More informationMAGNITUDE OF ANTIMICROBIAL USE. Antimicrobial Stewardship in Acute and Long Term Healthcare Facilities: Design, Implementation and Challenges
Antimicrobial Stewardship in Acute and Long Term Healthcare Facilities: Design, Implementation and Challenges John A. Jernigan, MD, MS Division of Healthcare Quality Promotion Centers for Disease Control
More information9/30/2016. Dr. Janell Mayer, Pharm.D., CGP, BCPS Dr. Lindsey Votaw, Pharm.D., CGP, BCPS
Dr. Janell Mayer, Pharm.D., CGP, BCPS Dr. Lindsey Votaw, Pharm.D., CGP, BCPS 1 2 Untoward Effects of Antibiotics Antibiotic resistance Adverse drug events (ADEs) Hypersensitivity/allergy Drug side effects
More informationGENERAL NOTES: 2016 site of infection type of organism location of the patient
GENERAL NOTES: This is a summary of the antibiotic sensitivity profile of clinical isolates recovered at AIIMS Bhopal Hospital during the year 2016. However, for organisms in which < 30 isolates were recovered
More informationUCSF guideline for management of suspected hospital-acquired or ventilatoracquired pneumonia in adult patients
Background/methods: UCSF guideline for management of suspected hospital-acquired or ventilatoracquired pneumonia in adult patients This guideline establishes evidence-based consensus standards for management
More informationInt.J.Curr.Microbiol.App.Sci (2017) 6(3):
International Journal of Current Microbiology and Applied Sciences ISSN: 2319-7706 Volume 6 Number 3 (2017) pp. 891-895 Journal homepage: http://www.ijcmas.com Original Research Article https://doi.org/10.20546/ijcmas.2017.603.104
More information2012 ANTIBIOGRAM. Central Zone Former DTHR Sites. Department of Pathology and Laboratory Medicine
2012 ANTIBIOGRAM Central Zone Former DTHR Sites Department of Pathology and Laboratory Medicine Medically Relevant Pathogens Based on Gram Morphology Gram-negative Bacilli Lactose Fermenters Non-lactose
More informationUpdate on Resistance and Epidemiology of Nosocomial Respiratory Pathogens in Asia. Po-Ren Hsueh. National Taiwan University Hospital
Update on Resistance and Epidemiology of Nosocomial Respiratory Pathogens in Asia Po-Ren Hsueh National Taiwan University Hospital Ventilator-associated Pneumonia Microbiological Report Sputum from a
More informationOriginal Articles. K A M S W Gunarathne 1, M Akbar 2, K Karunarathne 3, JRS de Silva 4. Sri Lanka Journal of Child Health, 2011; 40(4):
Original Articles Analysis of blood/tracheal culture results to assess common pathogens and pattern of antibiotic resistance at medical intensive care unit, Lady Ridgeway Hospital for Children K A M S
More informationAntibiotic utilization and Pseudomonas aeruginosa resistance in intensive care units
NEW MICROBIOLOGICA, 34, 291-298, 2011 Antibiotic utilization and Pseudomonas aeruginosa resistance in intensive care units Vladimíra Vojtová 1, Milan Kolář 2, Kristýna Hricová 2, Radek Uvízl 3, Jan Neiser
More informationCONTAGIOUS COMMENTS Department of Epidemiology
VOLUME XXIII NUMBER 1 July 2008 CONTAGIOUS COMMENTS Department of Epidemiology Bugs and Drugs Elaine Dowell, SM (ASCP), Marti Roe SM (ASCP), Ann-Christine Nyquist MD, MSPH Are the bugs winning? The 2007
More informationSHC Clinical Pathway: HAP/VAP Flowchart
SHC Clinical Pathway: Hospital-Acquired and Ventilator-Associated Pneumonia SHC Clinical Pathway: HAP/VAP Flowchart v.08-29-2017 Diagnosis Hospitalization (HAP) Pneumonia develops 48 hours following: Endotracheal
More informationAntibiotic Updates: Part II
Antibiotic Updates: Part II Fredrick M. Abrahamian, DO, FACEP, FIDSA Health Sciences Clinical Professor of Emergency Medicine David Geffen School of Medicine at UCLA Los Angeles, California Financial Disclosures
More informationKonsequenzen für Bevölkerung und Gesundheitssysteme. Stephan Harbarth Infection Control Program
Konsequenzen für Bevölkerung und Gesundheitssysteme Stephan Harbarth Infection Control Program University of Geneva Hospitals Outline Introduction What data sources are available? AMR-associated outcomes
More informationWitchcraft for Gram negatives
Witchcraft for Gram negatives Dr Subramanian S MD DNB MNAMS AB (Medicine, Infect Dis) Infectious Diseases Consultant Global Health City, Chennai www.asksubra.com Drug resistance follows the drug like a
More informationAntibiotic Resistance. Antibiotic Resistance: A Growing Concern. Antibiotic resistance is not new 3/21/2011
Antibiotic Resistance Antibiotic Resistance: A Growing Concern Judy Ptak RN MSN Infection Prevention Practitioner Dartmouth-Hitchcock Medical Center Lebanon, NH Occurs when a microorganism fails to respond
More informationRETROSPECTIVE STUDY OF GRAM NEGATIVE BACILLI ISOLATES AMONG DIFFERENT CLINICAL SAMPLES FROM A DIAGNOSTIC CENTER OF KANPUR
Original article RETROSPECTIVE STUDY OF GRAM NEGATIVE BACILLI ISOLATES AMONG DIFFERENT CLINICAL SAMPLES FROM A DIAGNOSTIC CENTER OF KANPUR R.Sujatha 1,Nidhi Pal 2, Deepak S 3 1. Professor & Head, Department
More informationAntibiotic usage in nosocomial infections in hospitals. Dr. Birgit Ross Hospital Hygiene University Hospital Essen
Antibiotic usage in nosocomial infections in hospitals Dr. Birgit Ross Hospital Hygiene University Hospital Essen Infection control in healthcare settings - Isolation - Hand Hygiene - Environmental Hygiene
More informationBurton's Microbiology for the Health Sciences. Chapter 9. Controlling Microbial Growth in Vivo Using Antimicrobial Agents
Burton's Microbiology for the Health Sciences Chapter 9. Controlling Microbial Growth in Vivo Using Antimicrobial Agents Chapter 9 Outline Introduction Characteristics of an Ideal Antimicrobial Agent How
More informationOutline. Antimicrobial resistance. Antimicrobial resistance in gram negative bacilli. % susceptibility 7/11/2010
Multi-Drug Resistant Organisms Is Combination Therapy the Way to Go? Sutthiporn Pattharachayakul, PharmD Prince of Songkhla University, Thailand Outline Prevalence of anti-microbial resistance in Acinetobacter
More informationMulti-drug resistant microorganisms
Multi-drug resistant microorganisms Arzu TOPELI Director of MICU Hacettepe University Faculty of Medicine, Ankara-Turkey Council Member of WFSICCM Deaths in the US declined by 220 per 100,000 with the
More informationGeneral Approach to Infectious Diseases
General Approach to Infectious Diseases 2 The pharmacotherapy of infectious diseases is unique. To treat most diseases with drugs, we give drugs that have some desired pharmacologic action at some receptor
More informationInteractive session: adapting to antibiogram. Thong Phe Heng Vengchhun Felix Leclerc Erika Vlieghe
Interactive session: adapting to antibiogram Thong Phe Heng Vengchhun Felix Leclerc Erika Vlieghe Case 1 63 y old woman Dx: urosepsis? After 2 d: intermediate result: Gram-negative bacilli Empiric antibiotic
More informationBest Practices: Goals of Antimicrobial Stewardship
Best Practices: Goals of Antimicrobial Stewardship Gail Scully, M.D, M.P.H. and Elizabeth Radigan, PharmD, BCPS UMass Memorial Medical Center Division of Infectious Disease Department of Medicine September
More informationConcise Antibiogram Toolkit Background
Background This toolkit is designed to guide nursing homes in creating their own antibiograms, an important tool for guiding empiric antimicrobial therapy. Information about antibiograms and instructions
More information03/09/2014. Infection Prevention and Control A Foundation Course. Talk outline
Infection Prevention and Control A Foundation Course 2014 What is healthcare-associated infection (HCAI), antimicrobial resistance (AMR) and multi-drug resistant organisms (MDROs)? Why we should be worried?
More informationIntrinsic, implied and default resistance
Appendix A Intrinsic, implied and default resistance Magiorakos et al. [1] and CLSI [2] are our primary sources of information on intrinsic resistance. Sanford et al. [3] and Gilbert et al. [4] have been
More informationSurveillance of Antimicrobial Resistance among Bacterial Pathogens Isolated from Hospitalized Patients at Chiang Mai University Hospital,
Original Article Vol. 28 No. 1 Surveillance of Antimicrobial Resistance:- Chaiwarith R, et al. 3 Surveillance of Antimicrobial Resistance among Bacterial Pathogens Isolated from Hospitalized Patients at
More informationNorthwestern Medicine Central DuPage Hospital Antimicrobial Criteria Updated 11/16/16
Northwestern Medicine Central DuPage Hospital Antimicrobial Criteria Updated 11/16/16 These criteria are based on national and local susceptibility data as well as Infectious Disease Society of America
More informationInfection Prevention Highlights for the Medical Staff. Pamela Rohrbach MSN, RN, CIC Director of Infection Prevention
Highlights for the Medical Staff Pamela Rohrbach MSN, RN, CIC Director of Infection Prevention Standard Precautions every patient every time a. Hand Hygiene b. Use of Personal Protective Equipment (PPE)
More informationCARBAPENEM RESISTANT ENTEROBACTERIACEAE (KPC CRE)
CARBAPENEM RESISTANT ENTEROBACTERIACEAE (KPC CRE) Bartsch SM et al. Potential economic burden of carbapenem-resistent Enterobacteriaceae (CRE) in the United States. Clin Microbiol Infect 2017;23(1):48e9-e16.
More informationTreatment Guidelines and Outcomes of Hospital- Acquired and Ventilator-Associated Pneumonia
SUPPLEMENT ARTICLE Treatment Guidelines and Outcomes of Hospital- Acquired and Ventilator-Associated Pneumonia Antoni Torres, Miquel Ferrer, and Joan Ramón Badia Pneumology Department, Clinic Institute
More informationPreventing Multi-Drug Resistant Organism (MDRO) Infections. For National Patient Safety Goal
Preventing Multi-Drug Resistant Organism (MDRO) Infections For National Patient Safety Goal 07.03.01 2009 Methicillin Resistant Staphlococcus aureus (MRSA) About 3-8% of the population at large is a carrier
More informationESISTONO LE HCAP? Francesco Blasi. Sezione Medicina Respiratoria Dipartimento Toraco Polmonare e Cardiocircolatorio Università degli Studi di Milano
ESISTONO LE HCAP? Francesco Blasi Sezione Medicina Respiratoria Dipartimento Toraco Polmonare e Cardiocircolatorio Università degli Studi di Milano Community-acquired pneumonia (CAP): Management issues
More informationThe β- Lactam Antibiotics. Munir Gharaibeh MD, PhD, MHPE School of Medicine, The University of Jordan November 2018
The β- Lactam Antibiotics Munir Gharaibeh MD, PhD, MHPE School of Medicine, The University of Jordan November 2018 Penicillins. Cephalosporins. Carbapenems. Monobactams. The β- Lactam Antibiotics 2 3 How
More informationFighting MDR Pathogens in the ICU
Fighting MDR Pathogens in the ICU Dr. Murat Akova Hacettepe University School of Medicine, Department of Infectious Diseases, Ankara, Turkey 1 50.000 deaths each year in US and Europe due to antimicrobial
More informationMechanism of antibiotic resistance
Mechanism of antibiotic resistance Dr.Siriwoot Sookkhee Ph.D (Biopharmaceutics) Department of Microbiology Faculty of Medicine, Chiang Mai University Antibiotic resistance Cross-resistance : resistance
More informationAntimicrobial Resistance. The Case for Diagnostics to Better Direct Therapy
Antimicrobial Resistance The Case for Diagnostics to Better Direct Therapy Objectives Explain the medical significance of antibiotic resistance Assess the medical impact of disease, such as pneumonia and
More informationPrevalence of Metallo-Beta-Lactamase Producing Pseudomonas aeruginosa and its antibiogram in a tertiary care centre
International Journal of Current Microbiology and Applied Sciences ISSN: 2319-7706 Volume 4 Number 9 (2015) pp. 952-956 http://www.ijcmas.com Original Research Article Prevalence of Metallo-Beta-Lactamase
More information1/30/ Division of Disease Control and Health Protection. Division of Disease Control and Health Protection
Surveillance, Outbreaks, and Reportable Diseases, Oh My! Assisted Living Facility, Nursing Home and Surveyor Infection Prevention Training February 2015 A.C. Burke, MA, CIC Health Care-Associated Infection
More information2015 Antimicrobial Susceptibility Report
Gram negative Sepsis Outcome Programme (GNSOP) 2015 Antimicrobial Susceptibility Report Prepared by A/Professor Thomas Gottlieb Concord Hospital Sydney Jan Bell The University of Adelaide Adelaide On behalf
More informationMulti-Drug Resistant Gram Negative Organisms POLICY REVIEW DATE EXTENDED Printed copies must not be considered the definitive version
Multi-Drug Resistant Gram Negative Organisms POLICY REVIEW DATE EXTENDED 2018 Printed copies must not be considered the definitive version DOCUMENT CONTROL POLICY NO. IC-122 Policy Group Infection Control
More informationANTIMICROBIAL STEWARDSHIP IN LONG TERM CARE FACILITIES
ANTIMICROBIAL STEWARDSHIP IN LONG TERM CARE FACILITIES ANTIMICROBIAL STEWARDSHIP COLLABORATIVE COLORADO HOSPITAL ASSOCIATION MARCH 23, 2016 Bridget Olson, RPh Infectious Disease Pharmacist, Sharp Coronado
More informationDATA COLLECTION SECTION BY FRONTLINE TEAM. Patient Identifier/ Medical Record number (for facility use only)
Assessment of Appropriateness of ICU Antibiotics (Patient Level Sheet) **Note this is intended for internal purposes only. Please do not return to PQC.** For this assessment, inappropriate antibiotic use
More informationCost high. acceptable. worst. best. acceptable. Cost low
Key words I Effect low worst acceptable Cost high Cost low acceptable best Effect high Fig. 1. Cost-Effectiveness. The best case is low cost and high efficacy. The acceptable cases are low cost and efficacy
More informationANTIMICROBIAL STEWARDSHIP: THE ROLE OF THE CLINICIAN SAM GUREVITZ PHARM D, CGP BUTLER UNIVERSITY COLLEGE OF PHARMACY AND HEALTH SCIENCES
ANTIMICROBIAL STEWARDSHIP: THE ROLE OF THE CLINICIAN SAM GUREVITZ PHARM D, CGP BUTLER UNIVERSITY COLLEGE OF PHARMACY AND HEALTH SCIENCES 1 Crisis: Antibiotic Resistance Success Strategy 2 OBJECTIVES Discuss
More informationAntimicrobial Susceptibility Patterns
Antimicrobial Susceptibility Patterns KNH SURGERY Department Masika M.M. Department of Medical Microbiology, UoN Medicines & Therapeutics Committee, KNH Outline Methodology Overall KNH data Surgery department
More informationAntibiotic stewardship in long term care
Antibiotic stewardship in long term care Shira Doron, MD Associate Professor of Medicine Division of Geographic Medicine and Infectious Diseases Tufts Medical Center Boston, MA Consultant to Massachusetts
More information10 Golden rules of Antibiotic Stewardship in ICU. Jeroen Schouten, MD PhD intensivist, Nijmegen (Neth) Istanbul, Oct 6th 2017
10 Golden rules of Antibiotic Stewardship in ICU Jeroen Schouten, MD PhD intensivist, Nijmegen (Neth) Istanbul, Oct 6th 2017 10 golden rules of Antibiotic Stewardship in the ICU ID, Pharma & Micro advice
More informationAvailable online at ISSN No:
Available online at www.ijmrhs.com ISSN No: 2319-5886 International Journal of Medical Research & Health Sciences, 2017, 6(4): 36-42 Comparative Evaluation of In-Vitro Doripenem Susceptibility with Other
More informationGUIDE TO INFECTION CONTROL IN THE HOSPITAL. Antibiotic Resistance
GUIDE TO INFECTION CONTROL IN THE HOSPITAL CHAPTER 4: Antibiotic Resistance Author M.P. Stevens, MD, MPH S. Mehtar, MD R.P. Wenzel, MD, MSc Chapter Editor Michelle Doll, MD, MPH Topic Outline Key Issues
More informationTrea%ng Sepsis in 2016 Are the Big Guns Losing the War?
Trea%ng Sepsis in 2016 Are the Big Guns Losing the War? ERIC HODGSON FCA (Crit Care) Inkosi Albert Luthuli Central Hospital & NELSON R MANDELA SCHOOL OF MEDICINE DURBAN, KZN Declaration Advisory boards
More informationMethicillin-Resistant Staphylococcus aureus Nasal Swabs as a Tool in Antimicrobial Stewardship
Methicillin-Resistant Staphylococcus aureus Nasal Swabs as a Tool in Antimicrobial Stewardship Natalie R. Tucker, PharmD Antimicrobial Stewardship Pharmacist Tyson E. Dietrich, PharmD PGY2 Infectious Diseases
More informationNew Drugs for Bad Bugs- Statewide Antibiogram
New Drugs for Bad Bugs- Statewide Antibiogram Felicia Matthews, Pharm.D., BCPS Senior Consultant, Pharmacy Specialty BE MedMined Services Disclosures Employee of BD Corporation MedMined Services Agenda
More informationRise of Resistance: From MRSA to CRE
Rise of Resistance: From MRSA to CRE Paul D. Holtom, MD Professor of Medicine and Orthopaedics USC Keck School of Medicine SUPERBUGS (AKA MDROs) MRSA Methicillin-resistant S. aureus Evolution of Drug Resistance
More informationEpidemiology and Burden of Antimicrobial-Resistant P. aeruginosa Infections
Epidemiology and Burden of Antimicrobial-Resistant P. aeruginosa Infections Keith S. Kaye, MD, MPH Professor of Medicine Division of Infectious Diseases Department of Internal Medicine University of Michigan
More informationAntimicrobial Pharmacodynamics
Antimicrobial Pharmacodynamics November 28, 2007 George P. Allen, Pharm.D. Assistant Professor, Pharmacy Practice OSU College of Pharmacy at OHSU Objectives Become familiar with PD parameters what they
More informationSuccessful stewardship in hospital settings
Successful stewardship in hospital settings Pr Charles-Edouard Luyt Service de Réanimation Institut de Cardiologie Groupe Hospitalier Pitié-Salpêtrière Université Pierre et Marie Curie, Paris 6 www.reamedpitie.com
More informationPreserving bacterial susceptibility Implementing Antimicrobial Stewardship Programs Debra A. Goff, Pharm.D., FCCP
Preserving bacterial susceptibility Implementing Antimicrobial Stewardship Programs Debra A. Goff, Pharm.D., FCCP Clinical Associate Professor Infectious Diseases Specialist The Ohio State University Medical
More informationBacterial infections complicating cirrhosis
PHC www.aphc.info Bacterial infections complicating cirrhosis P. Angeli, Dept. of Medicine, Unit of Internal Medicine and Hepatology (), University of Padova (Italy) pangeli@unipd.it Agenda Epidemiology
More informationSustaining an Antimicrobial Stewardship
Sustaining an Antimicrobial Stewardship Much needless expense, untoward effect, harm and disappointment can be prevented by better judgment in the use of antimicrobials Whitney A. Jones, PharmD Antimicrobial
More informationESBL- and carbapenemase-producing microorganisms; state of the art. Laurent POIREL
ESBL- and carbapenemase-producing microorganisms; state of the art Laurent POIREL Medical and Molecular Microbiology Unit Dept of Medicine University of Fribourg Switzerland INSERM U914 «Emerging Resistance
More informationManagement of hospital-acquired acquired pneumonia in the Asian Pacific region
Management of hospital-acquired acquired pneumonia in the Asian Pacific region Jae-Hoon Song, MD, PhD Samsung Medical Center Asian Network for Surveillance of Resistant Pathogens (ANSORP) Asian-Pacific
More informationOther Beta - lactam Antibiotics
Other Beta - lactam Antibiotics Assistant Professor Dr. Naza M. Ali Lec 5 8 Nov 2017 Lecture outlines Other beta lactam antibiotics Other inhibitors of cell wall synthesis Other beta-lactam Antibiotics
More informationDoes Screening for MRSA Colonization Have A Role In Healthcare-Associated Infection Prevention Programs?
Does Screening for MRSA Colonization Have A Role In Healthcare-Associated Infection Prevention Programs? John A. Jernigan, MD, MS Division of Healthcare Quality Promotion Centers for Disease Control and
More informationThese recommendations were approved for use by the Pharmaceutical and Therapeutics Committee, RCWMCH on 1 February 2017.
Antibiotic regimens for suspected hospital-acquired infection (HAI) outside the Paediatric Intensive Care Unit at Red Cross War Memorial Children s Hospital (RCWMCH) Lead author: Brian Eley Contributing
More informationEvaluating the Role of MRSA Nasal Swabs
Evaluating the Role of MRSA Nasal Swabs Josh Arnold, PharmD PGY1 Pharmacy Resident Pharmacy Grand Rounds February 28, 2017 2016 MFMER slide-1 Objectives Identify the pathophysiology of MRSA nasal colonization
More informationInappropriate Use of Antibiotics and Clostridium difficile Infection. Jocelyn Srigley, MD, FRCPC November 1, 2012
Inappropriate Use of Antibiotics and Clostridium difficile Infection Jocelyn Srigley, MD, FRCPC November 1, 2012 Financial Disclosures } No conflicts of interest } The study was supported by a Hamilton
More informationGram negative bacteraemia
Gram negative bacteraemia David Enoch Consultant Medical Microbiologist PHE Cambridge Cambridge University Hospitals NHS FT Overview Gram negative bacteraemia Changing epidemiology in England Epidemiology
More informationCollecting and Interpreting Stewardship Data: Breakout Session
Collecting and Interpreting Stewardship Data: Breakout Session Michael S. Calderwood, MD, MPH Regional Hospital Epidemiologist, Dartmouth-Hitchcock Medical Center March 20, 2019 None Disclosures Outline
More informationRESISTANT PATHOGENS. John E. Mazuski, MD, PhD Professor of Surgery
RESISTANT PATHOGENS John E. Mazuski, MD, PhD Professor of Surgery Disclosures Contracted Research: AstraZeneca, Bayer, Merck. Advisory Boards/Consultant: Allergan (Actavis, Forest Laboratories), AstraZeneca,
More informationTaiwan Crit. Care Med.2009;10: %
2008 30% 2008 2008 2004 813 386 07-346-8339 E-mail srwann@vghks.gov.tw 66 30% 2008 1 2008 2008 Intensive Care Med (2008)34:17-60 67 2 3 C activated protein C 4 5,6 65% JAMA 1995;273(2):117-23 Circulation,
More informationDetection of ESBL Producing Gram Negative Uropathogens and their Antibiotic Resistance Pattern from a Tertiary Care Centre, Bengaluru, India
ISSN: 2319-7706 Volume 4 Number 12 (2015) pp. 578-583 http://www.ijcmas.com Original Research Article Detection of ESBL Producing Gram Negative Uropathogens and their Antibiotic Resistance Pattern from
More informationHospital Acquired Infections in the Era of Antimicrobial Resistance
Hospital Acquired Infections in the Era of Antimicrobial Resistance Datuk Dr Christopher KC Lee Infectious Diseases Unit Department of Medicine Sungai Buloh Hospital Patient Story 23 Year old female admitted
More informationWhat bugs are keeping YOU up at night?
What bugs are keeping YOU up at night? Barbara DeBaun, RN, MSN, CIC 26 th Annual Medical Surgical Nursing Conference South San Francisco, CA April 15, 2016 Objectives Describe the top three infectious
More informationFlorida Health Care Association District 2 January 13, 2015 A.C. Burke, MA, CIC
Florida Health Care Association District 2 January 13, 2015 A.C. Burke, MA, CIC 11/20/2014 1 To describe carbapenem-resistant Enterobacteriaceae. To identify laboratory detection standards for carbapenem-resistant
More informationMultidrug-Resistant Organisms: How Do We Define them? How do We Stop Them?
Multidrug-Resistant Organisms: How Do We Define them? How do We Stop Them? Roberta B. Carey, PhD Centers for Disease Control and Prevention Division of Healthcare Quality Promotion Why worry? MDROs Clinical
More informationOverview of Nosocomial Infections Caused by Gram-Negative Bacilli
HEALTHCARE EPIDEMIOLOGY Robert A. Weinstein, Section Editor INVITED ARTICLE Overview of Nosocomial Infections Caused by Gram-Negative Bacilli Robert Gaynes, Jonathan R. Edwards, and the National Nosocomial
More informationJump Starting Antimicrobial Stewardship
Jump Starting Antimicrobial Stewardship Amanda C. Hansen, PharmD Pharmacy Operations Manager Carilion Roanoke Memorial Hospital Roanoke, Virginia March 16, 2011 Objectives Discuss guidelines for developing
More informationSimilar to Penicillins: -Chemically. -Mechanism of action. -Toxicity.
Similar to Penicillins: -Chemically. -Mechanism of action. -Toxicity. Cephalosporins are divided into Generations: -First generation have better activity against gram positive organisms. -Later compounds
More informationWhat does multiresistance actually mean? Yohei Doi, MD, PhD University of Pittsburgh
What does multiresistance actually mean? Yohei Doi, MD, PhD University of Pittsburgh Disclosures Merck Research grant Clinical context of multiresistance Resistance to more classes of agents Less options
More informationNational Clinical Guideline Centre Pneumonia Diagnosis and management of community- and hospital-acquired pneumonia in adults
National Clinical Guideline Centre Antibiotic classifications Pneumonia Diagnosis and management of community- and hospital-acquired pneumonia in adults Clinical guideline 191 Appendix N 3 December 2014
More informationPIPERACILLIN- TAZOBACTAM INJECTION - SUPPLY PROBLEMS
PIPERACILLIN- TAZOBACTAM INJECTION - SUPPLY PROBLEMS The current supply of piperacillin- tazobactam should be reserved f Microbiology / Infectious Diseases approval and f neutropenic sepsis, severe sepsis
More informationOPTIMIZATION OF PK/PD OF ANTIBIOTICS FOR RESISTANT GRAM-NEGATIVE ORGANISMS
HTIDE CONFERENCE 2018 OPTIMIZATION OF PK/PD OF ANTIBIOTICS FOR RESISTANT GRAM-NEGATIVE ORGANISMS FEDERICO PEA INSTITUTE OF CLINICAL PHARMACOLOGY DEPARTMENT OF MEDICINE, UNIVERSITY OF UDINE, ITALY SANTA
More informationESBL Producers An Increasing Problem: An Overview Of An Underrated Threat
ESBL Producers An Increasing Problem: An Overview Of An Underrated Threat Hicham Ezzat Professor of Microbiology and Immunology Cairo University Introduction 1 Since the 1980s there have been dramatic
More information2017 Introduction to Infectious Diseases Clinical Seminar Saturday 30th September - Sunday 1st October 2017 Hotel Grand Chancellor Hobart, Tasmania
2017 Introduction to Infectious Diseases Clinical Seminar Saturday 30th September - Sunday 1st October 2017 Hotel Grand Chancellor Hobart, Tasmania Day 1: Saturday 30 th September 2017 09:00 09:20 Registration
More informationDrug Class Prior Authorization Criteria Intravenous Antibiotics
Drug Class Prior Authorization Criteria Intravenous Antibiotics Line of Business: Medicaid P&T Approval Date: August 15, 2018 Effective Date: October 1, 2018 This drug class prior authorization criteria
More informationAntimicrobial Susceptibility Testing: Advanced Course
Antimicrobial Susceptibility Testing: Advanced Course Cascade Reporting Cascade Reporting I. Selecting Antimicrobial Agents for Testing and Reporting Selection of the most appropriate antimicrobials to
More information